Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

ATAI

AtaiBeckley Inc

5.07

Jul 07 • 12:12PM ET +0.11 (2.12%)

Healthcare Biotechnology USA Small NASD

Jul 06, 6:05 AMAtaiBeckley doses last patient in Phase 2b Elumina trial of VLS-01 for treatment-resistant depression, expects topline data in Q4 2026

Peers: ACAD AXSM RYTM BMRN INCY KRYS KYMR NUVL MDGL NBIX

| Held by: IWM VTI ARKG IWO IBB VXF XPH FYC SCHA PSIL

Scroll to Statements

Index	RUT
Market Cap	1.86B
Enterprise Value	1.64B
Income	-663.40M
Sales	3.49M
Book/sh	0.54
Cash/sh	0.63
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	117
IPO	Jun 18, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	534.32
P/B	9.32
P/C	8.08
P/FCF	-
EV/EBITDA	-
EV/Sales	468.80
Quick Ratio	10.02
Current Ratio	10.02
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-2.24
EPS next Y	-0.45
EPS next Q	-0.11
EPS this Y	85.14%
EPS next Y	-2.94%
EPS next 5Y	46.41%
EPS past 3/5Y	-43.86% 36.94%
Sales past 3/5Y	159.87% -
EPS Y/Y TTM	-178.33%
Sales Y/Y TTM	-
EPS Q/Q	44.43%
Sales Q/Q	-38.65%
Earnings	May 12 BMO
EPS/Sales Surpr.	25.09% 339.43%

Insider Own	20.10%
Insider Trans	-0.06%
Inst Own	26.29%
Inst Trans	16.34%
ROA	-
ROE	-
ROIC	-331.08%
Gross Margin	-
Oper. Margin	-3658.03%
Profit Margin	-19019.44%
SMA20	14.82%
SMA50	17.33%
SMA200	17.85%
Trades

Shs Outstand	365.56M
Shs Float	294.15M
Short Float	8.01%
Short Ratio	3.24
Short Interest	23.55M
52W High	6.75 -24.96%
52W Low	2.53 100.20%
Volatility	9.00% 8.97%
ATR (14)	0.38
RSI (14)	60.88
Beta	1.59
Rel Volume	0.98
Avg Volume	7.27M
Volume	3,161,819

Perf Week	-5.50%
Perf Month	12.56%
Perf Quarter	31.56%
Perf Half Y	30.88%
Perf YTD	23.84%
Perf Year	84.18%
Perf 3Y	148.28%
Perf 5Y	-71.06%
Perf 10Y	-
Recom	1.00
Target Price	13.85
Prev Close	4.96
Price	5.07
Change	2.12%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-27-26	Initiated	Deutsche Bank	Buy	$12
Jan-20-26	Initiated	Guggenheim	Buy	$11
Oct-13-25	Initiated	Needham	Buy	$12
Jul-29-25	Initiated	Oppenheimer	Outperform	$14
Nov-18-24	Reiterated	H.C. Wainwright	Buy	$15 → $10
Apr-03-24	Upgrade	Maxim Group	Hold → Buy	$6
Nov-01-22	Initiated	Loop Capital	Buy	$18
Nov-30-21	Initiated	Maxim Group	Buy	$25
Nov-11-21	Initiated	ROTH Capital	Buy	$32
Oct-18-21	Initiated	H.C. Wainwright	Buy	$40
Sep-01-21	Initiated	Jefferies	Buy	$27
Jul-13-21	Initiated	RBC Capital Mkts	Sector Perform	$19
Jul-13-21	Initiated	Credit Suisse	Outperform	$25
Jul-13-21	Initiated	Cowen	Outperform
Jul-13-21	Initiated	Citigroup	Buy	$26
Jul-13-21	Initiated	Cantor Fitzgerald	Buy	$45
Jul-13-21	Initiated	Canaccord Genuity	Buy	$28
Jul-13-21	Initiated	Berenberg	Buy	$35
Jul-08-21	Initiated	Aegis Capital	Buy	$26

Show Previous Ratings

Jul-06-26 08:40AM	AtaiBeckley completes dosing in Phase 2b depression trial, expects topline data in Q4 (Proactive)
06:00AM	AtaiBeckley Doses Last Patient in VLS-01 Phase 2b TRD Study; Plans Phase 3 in Major Depressive Disorder (GlobeNewswire)
Jun-25-26 09:03AM	AtaiBeckley to join Russell 2000 and Russell 3000 indexes following annual reconstitution (Proactive) +9.83%
06:00AM	AtaiBeckley to Join the Russell Indexes, Expanding Visibility Across U.S. Equity Markets (GlobeNewswire)
Jun-04-26 01:38PM	AtaiBeckley nears key clinical catalysts, Jefferies stays positive with repeat Buy rating (Proactive)
09:57AM	Loading…
May-28-26 09:57AM	AtaiBeckley launches mental health patient impact grant program (Proactive)
09:00AM	AtaiBeckley Launches Patient Impact Grant Program for Mental Health Non-Profit Organizations (GlobeNewswire)
May-27-26 06:00AM	AtaiBeckley to Participate in Upcoming Investor Conferences in June 2026 (GlobeNewswire)
May-13-26 01:06PM	AtaiBeckley clinical pipeline advances toward multiple late-stage data catalysts, Jefferies says (Proactive)
May-12-26 09:22AM	AtaiBeckley targets Q2 start for Phase 3 depression trial as pipeline advances (Proactive)
08:00AM	AtaiBeckley Reports First Quarter 2026 Financial Results and Provides Program and Business Update (GlobeNewswire)
Apr-27-26 08:22AM	AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials (Proactive) -6.26%
04:05AM	AtaiBeckley and PsyPAN Receive a Silver Award in 2026 Patient Participant Index, Reflecting Ongoing Commitment to Participant-Informed Research (GlobeNewswire)
Apr-24-26 03:59PM	FDA Fast-Tracks Review of Some Psychedelic Drugs. This Stock Is Set to Benefit. (Barrons.com)
11:58AM	Psychedelic Pharma Stocks Are Riding High. Past Cannabis Returns Are a Reality Check. (Barrons.com)
08:49AM	Loading…
Apr-22-26 08:49AM	Can I have some, please?: Trump jokes as he signs psychedelics order after Joe Rogan push. These stocks soar (Moneywise)
Apr-20-26 12:41PM	Trump Signs Psychedelic Drugs Order. 4 Stocks That Are Surging. (Barrons.com) +21.59%
11:48AM	Trump Pushes for Speedy Psychedelic Approvals, Sending Stocks Surging (The Wall Street Journal)
09:56AM	Psychedelics stocks rise after Trump order expands research, access pathways (Proactive)
08:26AM	Psychedelic stocks rally with Trump's support (MarketWatch)
08:18AM	Trump Signs Order to Fast-Track Psychedelic Drugs. AtaiBeckley and These Other Stocks Are Soaring. (Barrons.com)
05:53AM	Psychedelic stocks soar after Trump signs executive order to fast-track treatments (Investing.com)
Apr-14-26 11:18AM	Johnson & Johnsons Spravato sales growth signals upside for psychedelics peers (Proactive)
Apr-08-26 08:40AM	AtaiBeckley reports rapid response in Phase 2a trial of depression drug BPL-003 (Proactive)
06:00AM	AtaiBeckley's BPL-003 Shows Rapid, Durable Antidepressant Response in Treatment-Resistant Depression Patients on SSRIs; Phase 2a Data Published in CNS Drugs (GlobeNewswire)
Mar-29-26 10:25AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-27-26 11:25AM	AtaiBeckley awarded Buy rating in initial coverage from Deutsche Bank analysts (Proactive) -5.37%
Mar-24-26 08:36AM	AtaiBeckley added to major US indices, increasing reach among passive investors (Proactive)
06:00AM	AtaiBeckley Joins $3 Trillion CRSP Index and S&P Benchmark Indices Adding Mandatory Passive Fund Ownership to Phase 3 Pipeline Catalyst (GlobeNewswire)
Mar-17-26 09:09AM	AtaiBeckley reports rapid, sustained antidepressant effects in Phase 2a study of BPL-003 (Proactive)
06:00AM	Loading…
06:00AM	BPL-003 Demonstrates Rapid and Durable Antidepressant Effects in Treatment-Resistant Depression; Phase 2a Data Published in Journal of Psychopharmacology; Phase 3 Program on Track for Q2 2026 Initiation (GlobeNewswire)
Mar-10-26 10:45AM	AtaiBeckley outlines plans for Phase 3 trials of BPL-003 in treatment-resistant depression at Investor Day (Proactive) +6.43%
06:00AM	BPL-003 Phase 3 Program Initiation on Track for Q2 2026 Following Successful FDA End-of-Phase 2 Meeting; AtaiBeckley Highlights Key Pipeline Milestones at 2026 Investor Day (GlobeNewswire)
Mar-09-26 10:50AM	CNS Drug Developers Add Pharma Veterans as Sector Nears First FDA Decisions (PR Newswire) +14.75%
Mar-08-26 12:57PM	AtaiBeckley (ATAI) Reports 2025 Results and Q2 2026 Phase 3 Launch for BPL-003 (Insider Monkey)
11:17AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Mar-06-26 10:15AM	Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results (TipRanks)
08:41AM	AtaiBeckley reports 2025 results as it eyes Q2 start for Phase 3 depression trial (Proactive)
07:00AM	AtaiBeckley Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business and Clinical Update (GlobeNewswire)
Mar-05-26 10:38AM	Helus Pharma Stock Tumbles As Anxiety Drug Study Disappoints (Benzinga)
Mar-04-26 11:40AM	AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting (Insider Monkey)
05:39AM	AtaiBeckley Inc (ATAI)'s Drug Candidate EMP-01 Shows Positive Results in Key Study (Insider Monkey)
Mar-03-26 08:07AM	AtaiBeckley cleared for Phase 3 trials of nasal spray depression treatment after FDA backing (Proactive)
07:00AM	AtaiBeckley Announces Successful End-of-Phase 2 Meeting for BPL-003 in Treatment-Resistant Depression (GlobeNewswire)
Feb-27-26 11:44AM	Psychedelic Biotechs Push Toward Phase 3: Five Companies Advancing CNS Treatments (PR Newswire)
06:58AM	Cathie Wood "Buys the Dip" in Baidu Stock -- Should You? (GuruFocus.com)
Feb-26-26 03:49PM	Dow Jones back level but Nasdaq in the red thanks to Nvidia (Proactive) -14.06%
09:49AM	AtaiBeckley Touts Social Anxiety Breakthrough With Phase 2 Trial Data (Benzinga)
09:47AM	AtaiBeckley reports positive results from Phase 2a social anxiety disorder trial (Proactive)
07:00AM	AtaiBeckley Announces Positive Topline Results from an Exploratory Phase 2a Trial of EMP-01 (oral R-MDMA) in Social Anxiety Disorder (GlobeNewswire)
Feb-20-26 07:00AM	AtaiBeckley To Host Virtual Investor Day on March 6, 2026 (GlobeNewswire)
Feb-19-26 03:30PM	Dow Jones leads Wall Street lower, US-Iran fears drive oil higher (Proactive)
08:21AM	AtaiBeckley names Michael Faerm as finance chief (Proactive)
07:00AM	AtaiBeckley Appoints Michael Faerm as Chief Financial Officer (GlobeNewswire)
Feb-17-26 07:00AM	AtaiBeckley To Participate in Upcoming Investor Conferences (GlobeNewswire) +6.44%
Feb-15-26 04:08AM	Wall Street Bullish on AtaiBeckley (ATAI), Here's Why (Insider Monkey)
Feb-13-26 11:44AM	Here's What Analysts Are Saying About AtaiBeckley Inc. (ATAI) (Insider Monkey)
07:13AM	AtaiBeckley Inc. (ATAI) Gains Momentum With Promising BPL-003 Data and Strong Analyst Support (Insider Monkey)
Jan-30-26 02:58PM	Guggenheim Initiates Buy Rating for AtaiBeckley (ATAI) With $11 PT, Cites Leadership in Psychiatry (Insider Monkey)
Jan-29-26 01:48PM	H.C. Wainwright Remains Bullish on AtaiBeckley Inc. (ATAI) (Insider Monkey)
Jan-19-26 11:28AM	High Risk, High Reward: 3 Healthcare Stocks to Watch in 2026 (MarketBeat)
Jan-18-26 12:30PM	Atai Beckley N.V. (ATAI) Achieves Significant Milestone on Pipeline Development and Corporate Foundation (Insider Monkey)
Jan-16-26 07:00AM	AtaiBeckley Participates in the 64th Annual ACNP Meeting with Two Scientific Poster Presentations and Hot Topic Presentation (GlobeNewswire)
Jan-14-26 02:13PM	Atai Beckley N.V. (ATAI) is a Buy on Mental Therapeutics Opportunities (Insider Monkey)
Jan-13-26 04:01AM	New Strong Sell Stocks for Jan. 13 (Zacks)
Jan-09-26 07:17AM	Atai Beckley CEO says entering 2026 with meaningful momentum (TipRanks) -5.54%
Jan-08-26 07:00AM	AtaiBeckley Provides Update and Outlook for 2026 Ahead of J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-04-26 04:51PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Dec-30-25 06:55PM	AtaiBeckley Completes Redomiciliation to the United States (GlobeNewswire)
Dec-27-25 07:43AM	JonesTrading Highlights Differentiated Pipeline at Atai Beckley N.V. (ATAI) (Insider Monkey)
Dec-25-25 08:30AM	The 1 Riskiest Investment That Paid Off in 2025 (Barchart)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
07:00AM	AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Dec-22-25 01:12PM	MarketBeat's Top 5 Rated Small-Cap Stocks (MarketBeat) +8.59%
Dec-18-25 01:14AM	Atai Life Sciences N.V. (ATAI) Secures Patent for Social Anxiety Disorder Formulation (Insider Monkey)
Dec-15-25 08:03AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Dec-11-25 07:00AM	AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio (GlobeNewswire)
Nov-25-25 08:39AM	H.C. Wainwright Maintains Buy on Atai Beckley (ATAI) Following Breakthrough Therapy and Merger Completion (Insider Monkey)
Nov-19-25 07:32PM	Enhanced Fortifies Executive Leadership Team & Board of Directors (PR Newswire)
Nov-18-25 06:16AM	Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato (Insider Monkey)
Nov-13-25 09:00AM	AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-12-25 07:00AM	AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Nov-10-25 07:00AM	AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression (GlobeNewswire)
Nov-05-25 07:00AM	atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies (GlobeNewswire) -15.15%
Oct-20-25 05:29PM	atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares (GlobeNewswire) -8.57%
12:00PM	atai Life Sciences (ATAI) Upgraded to Buy: Here's Why (Zacks)
Oct-17-25 08:06AM	Why Atai Life Sciences Stock Was So Lively This Week (Motley Fool) +17.70%
Oct-16-25 10:31PM	atai Life Sciences Announces Pricing of Public Offering of Common Shares (GlobeNewswire) -8.05%
04:12PM	atai Life Sciences Announces Proposed Public Offering of Common Shares (GlobeNewswire)
04:10PM	atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression (GlobeNewswire)
Sep-24-25 07:09AM	atai and Beckleys psychedelic advances to pivotal TRD trial (Clinical Trials Arena)
Sep-23-25 07:21PM	Atai Life Sciences N.V. (ATAI) Advances Psychedelic Therapies for Mental Health, Drawing Investor Spotlight (Insider Monkey) +14.96%
05:51PM	Why Atai Life Sciences Stock Crushed It on Tuesday (Motley Fool)
02:50PM	Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients (Benzinga)
07:00AM	atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression (GlobeNewswire)
Sep-21-25 09:06PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-20-25 02:43AM	H.C. Wainwright Affirms 'Buy' Rating on Atai Life Sciences N.V. (ATAI) on Psychedelic Prospects (Insider Monkey)
Sep-19-25 09:40AM	Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year? (Zacks)
08:10AM	Atai Life Sciences awarded grant worth up to $11.4M from NIH (TipRanks)
Sep-18-25 08:00AM	atai Life Sciences Awarded Grant from the National Institutes of Health (GlobeNewswire)

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

Co-Founder & Chairman of the BoardMr. Christian Angermayer

Ph.D.Dr. Srinivas G. Rao M.D.

Chief Operating OfficerDr. Gerd G. Kochendoerfer Ph.D.

Chief Legal & Business OfficerMr. Ryan Barrett J.D.

Chief Financial OfficerMr. Michael Eric Faerm

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GERD KOCHENDOERFER	Officer	Jun 26 '26	Proposed Sale	4.58	50,000	229,000		Jun 26 04:24 PM
KEVIN CRAIG	Officer	Jun 25 '26	Proposed Sale	4.17	85,158	355,109		Jun 25 04:27 PM
Craig Kevin James	Chief Medical Officer	Apr 20 '26	Option Exercise	1.62	42,579	69,070	51,016	Apr 22 05:32 PM
Craig Kevin James	Chief Medical Officer	Apr 20 '26	Sale	5.00	42,579	212,895	8,437	Apr 22 05:32 PM
KEVIN JAMES CRAIG	Officer	Apr 20 '26	Proposed Sale	4.03	42,579	171,593		Apr 20 04:34 PM
Angermayer Christian	Director	Apr 08 '26	Option Exercise	1.60	559,232	897,297	559,232	Apr 10 06:00 PM
KEVIN JAMES CRAIG	Officer	Mar 20 '26	Proposed Sale	3.57	100,000	357,000		Mar 20 04:41 PM
Feilding-Mellen Cosmo	Director	Feb 26 '26	Proposed Sale	4.00	750,000	3,000,000		Feb 26 04:11 PM
Apeiron Investment Group Ltd.	10% Owner	Aug 14 '25	Buy	2.19	8,675,799	19,000,000	51,045,214	Aug 18 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATAI

AtaiBeckley Inc

Upgrade your Finviz experience